CA-AFFINITY
16.6.2022 13:02:11 CEST | Business Wire | Press release
Affinity — the relationship intelligence platform for dealmakers— today launched The Relationship Intelligence Benchmark Report: Unicorn Edition , which shares industry trends and analyzes over 390 unicorns in Europe and the United Kingdom with a deep dive into relationship intelligence and deal flows of the firms that invest in them.
Integrated data from the Affinity and Dealroom.co’s intelligence platforms found Europe has a unicorn growth rate more than twice that of the US and is home to 65 “unicorn cities.” These unicorn cities consist of London, Berlin, Paris, Stockholm, and Amsterdam, with more than half of all European unicorns located in the UK and Germany. Recognizing the growth internationally, U.S. investors have flocked to join and now account for 35% of all funding in Europe. This flood of investment has also increased unicorn valuations which are up by 305% in the last five years.
“The past decade has seen an exponential increase in the volume and diversity of new capital investing in startups - and is now entering turbulent economic times,” said Ray Zhou, co-CEO and co-founder at Affinity. “Our report highlights how Europe has adapted and grown, despite the effects of the pandemic, and shows how relationship intelligence plays a role in these major industry trends.”
As expected, many firms experienced a period of “bounce back” from 2020. In 2021, European unicorns raised over $45B, twice the amount raised in 2020. However, these unicorns only account for 14% of new unicorns globally. This means the competition among VC’s is significant as they try to time the right investment. Index Ventures is a single venture responsible for backing 10 European decacorns by itself. The combination of high valuations and less late-stage funding rounds requires VC’s to capitalize on their networks, warm introductions, and outreach. But as these firms and startups face uncertain economic conditions, it is important to understand the drivers for the previous success and how investors identify the next generation of high-growth startups in Europe.
Other key takeaways from the report include:
- Unicorns are roaming : Europe produced 5 times more unicorns in 2021 than in 2020.
- Germany is now a hotspot : German funding of unicorns grew over 300% in the last 5 years. Together with the UK, they have funded 2/3 of all Europe-based unicorns.
- Decacorns are on the rise : Over the past five years, this percentage of multibillion-dollar unicorns has risen by a staggering 560%. The total value of decacorns in 2021 was $777.4B; to date in 2022 is at $718.3B, guaranteeing it will exceed 2021’s numbers.
- The rebound is over : While firms saw an increase in deals, meetings and email volume in 2021, the beginning of 2022 tells a different story. In the first quarter of 2022, firms experienced 27% less meetings and deals, likely due to the inflation in Europe and predictions of an impending recession.
Read the full report here and then watch Affinity’s webinar “European Unicorn Trends: How to Make Unicorn Hunting More Predictable ,” which brings industry experts together to discuss the trends impacting dealmakers in this report as well as the role relationship intelligence plays in the evolving market landscape.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations worldwide. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors, including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005351/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
